NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

The Competitive Effects of Drug Withdrawals

John Cawley, John A. Rizzo

NBER Working Paper No. 11223
Issued in March 2005
NBER Program(s):   HC

In September 1997, the anti-obesity drugs Pondimin and Redux, ingredients in the popular drug combination fen-phen, were withdrawn from the market for causing potentially fatal side effects. That event provides an opportunity for studying how consumers respond to drug withdrawals. In theory, remaining drugs in the therapeutic class could enjoy competitive benefits, or suffer negative spillovers, from the withdrawal of a competing drug. Our findings suggest that, while the withdrawal of a rival drug may impose negative spillovers in the form of higher patient quit rates, on the whole non-withdrawn drugs in the same therapeutic class enjoy competitive benefits in the form of higher utilization.

download in pdf format
   (258 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

This paper is available as PDF (258 K) or via email.

This paper was revised on February 8, 2006

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w11223

Published: Cawley, John, and John A. Rizzo. “Spillover Effects of Prescription Drug Withdrawals.” Advances in Health Economics and Health Services Research, 2008, 19: 119-144.

Users who downloaded this paper also downloaded these:
Rizzo and Zeckhauser w11431 Generic Scrip Share and the Price of Brand-Name Drugs: The Role of the Consumer
 
Publications
Activities
Meetings
NBER Videos
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us